- Previous Close
1.3800 - Open
1.3800 - Bid 1.3000 x --
- Ask 1.3350 x --
- Day's Range
1.3000 - 1.4000 - 52 Week Range
1.2250 - 22.5556 - Volume
35,238 - Avg. Volume
22,356 - Market Cap (intraday)
17.251M - Beta (5Y Monthly) 0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-91.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children's Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
www.aptahem.comRecent News: APTA.ST
View MorePerformance Overview: APTA.ST
Trailing total returns as of 11/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: APTA.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: APTA.ST
View MoreValuation Measures
Market Cap
17.25M
Enterprise Value
13.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.27
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-9.24%
Return on Equity (ttm)
-18.26%
Revenue (ttm)
2.65M
Net Income Avi to Common (ttm)
-11.22M
Diluted EPS (ttm)
-91.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
3.6M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-22.81M